Insider buying last 90 days
No open-market insider purchases were filed for TEVA in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every TEVA insider filing, plotted on the chart in Gekko.Open TEVA in Gekko
Teva Pharmaceutical Industries (TEVA) Stock Analysis & Forecast
$38.98−0.21 (−0.5%)
Close on Sep 18, 2026. Page updated Sep 19, 9:19 pm ET.
Gekko Brief
AI summaryTeva closes at $38.98, down 0.5% on the day and near its 52-week high of $39.70, well above both the 50-day ($35.35) and 200-day ($33.15) moving averages, with the shorter average sitting above the longer one. The GekkoIndex reads 50.5, placing the stock in the Neutral zone after a five-point pullback recently. Against this, the price sits 23.5% above Gekko Fair Value of $31.56, a gap that stands out relative to the trend readings.
Recent coverage centers on Teva's "Pivot to Growth" strategy, with branded medicines, generics, and biosimilars described as exceeding expectations, alongside a debt refinancing and a shift to trading directly on the NYSE. Product-focused releases this week highlighted new data on AUSTEDO for tardive dyskinesia, UZEDY for schizophrenia continuity and cost outcomes, and post hoc results for the olanzapine LAI candidate TEV-'749 from the SOLARIS Phase 3 trial. A separate report also flagged unusual options volume in TEVA alongside FPS and AFL.
Looking ahead, Teva's next earnings date falls on 4 November, 45 days out and beyond a typical 20-trading-day holding window; the prior report on 29 July showed EPS of $0.64 against a $0.05 estimate with an 11.8% reaction, part of a run of 7 beats in the last 8 quarters. No insider, Congress, or unusual options activity appears in the current windows. Seasonally, the next 20 trading days have averaged a -0.6% return over 5 years, positive in 3 of those years, a pattern worth noting given the current gap to fair value.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $38.98200-day averageGekko Fair Value $31.56
Key stats
- Market cap
- $45.40B
- P/E ratio
- 64.3
- Forward P/E
- 12.6
- EPS, TTM
- $0.61
- Revenue, TTM
- $17.32B
- Profit margin
- 4.1%
- Dividend yield
- —
- Beta
- 0.87
- Volume
- 5.47M avg 4.65M
- 1-year return
- +112.1%
- Typical daily move
- ±3.1%
- Typical 20-day move
- ±7.9%
- 50-day average
- $35.35
- 200-day average
- $33.15
- Next earnings
- Nov 4 before open
- Shares outstanding
- 1.17B
Teva Pharmaceutical Industries swing-trade checklist
Teva Pharmaceutical Industries scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $38.98 is above the 50-day ($35.35) and 200-day ($33.15) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
50.5, Neutral
Reading 50.5 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
23.5% above
Price is 23.5% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 45 days
Next report Nov 4, 2026, 45 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
−0.6% on average
From this point in the calendar, the next 20 trading days averaged −0.6% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Teva Pharmaceutical Industries stock chart and price history
Teva Pharmaceutical Industries closed at $38.98 on Sep 18, 2026, +112.1% over the past year, inside a 52-week range of $18.21 to $39.70.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +4.0%
- 3 months
- +23.8%
- 6 months
- +32.4%
- 1 year
- +112.1%
The full TEVA chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open TEVA in Gekko
Follow Teva Pharmaceutical Industries through every session
Put TEVA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track TEVA in GekkoFree for 7 days. No credit card required.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries makes and sells medicines worldwide, spanning generic drugs, specialty treatments and biopharmaceuticals for patients across North America, Europe and other regions. Its manufacturing covers sterile products, hormones, potent compounds and cytotoxic agents, formulated as tablets, capsules, injections, inhalers, liquids, patches and topical creams. The company also produces active pharmaceutical ingredients used in drug manufacturing. It has built recognition around treatments for central nervous system conditions, including Copaxone for multiple sclerosis, AJOVY for migraine prevention and AUSTEDO for tardive dyskinesia and Huntington's-related chorea.
Beyond neurology, Teva supplies respiratory treatments such as ProAir, QVAR and several Digihaler and RespiClick inhaler lines for asthma and COPD, alongside oncology products including Bendeka, Treanda, Granix and Trisenox. It also works with MedinCell on long-acting injectable formulations, among them a risperidone-based treatment for schizophrenia. Its offerings reach patients and healthcare providers through these therapeutic categories rather than a single product line.
Teva traces its founding to 1901 and is headquartered in Tel Aviv-Yafo, Israel. Its shares trade under the ticker TEVA.
- Sector
- Health technology
- Website
- tevapharm.com
Teva Pharmaceutical Industries GekkoIndex: the smart money zone
Teva Pharmaceutical Industries’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 50.5, in the Neutral zone, down 6 points over five sessions.
50.5Neutral
Down 6 points over five sessions.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 19 | −1.5% | +3.9% | ||
| Accumulation | 146 | +1.6% | +8.6% | ||
| Neutral (current zone) | 390 | +0.9% | +2.6% | ||
| Distribution | 59 | +0.1% | +2.1% | ||
| Selling | 1 | Too few readings yet | |||
Average TEVA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the TEVA price, zone by zone.Track TEVA in Gekko
Is Teva Pharmaceutical Industries stock overvalued? Gekko Fair Value
Teva Pharmaceutical Industries trades 23.5% above Gekko Fair Value of $31.56, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Teva Pharmaceutical Industries shares are worth, recalculated every trading day.
$31.56
Gekko Fair Value, Sep 19, 2026
23.5% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open TEVA in Gekko
Teva Pharmaceutical Industries insider and Congress trading
No open-market insider purchases were filed for Teva Pharmaceutical Industries, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in TEVA were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for TEVA, plotted on the chart in Gekko.Open TEVA in Gekko
Hedge funds and billionaires quarter ended Jun 30
3of the funds Gekko tracks hold TEVA.
0added0opened3trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Teva Pharmaceutical Industries earnings: next date and track record
Teva Pharmaceutical Industries reports on Nov 4, 2026, before the open (45 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected before the open, 45 days away
- EPS estimate
- $0.71
- Revenue estimate
- $4.26B
7 of 8reports beat the EPS estimate
±10.8%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 29, 2026 AI summary
- What they said
- Teva Q2 2026 showed stable revenues despite ~8% headwind from generic REVLIMID loss, with innovative portfolio up 43% YoY. AUSTEDO grew 40% to $676M US revenue, UZEDY rose 43% to $77M, and AJOVY jumped 56%. Gross margins improved 80bps YoY, EBITDA grew ex-Amylyx acquisition, and free cash flow increased 31%. Teva upgraded by Fitch to investment grade and closed Amylyx acquisition in June.
- Guidance
- AUSTEDO guidance raised $50M at midpoint to $2.45B-$2.6B for full year, with peak sales target above $3B. UZEDY guidance increased $15M at midpoint to $270M-$290M. Olanzapine LAI FDA action and US launch anticipated Q4 2026.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 29, 2026 | $0.64 est $0.05 | $4.14B est $4.02B | +11.8% |
| Apr 29, 2026 | $0.53 est $0.46 | $3.98B est $3.79B | +10.9% |
| Jan 28, 2026 | $0.96 est $0.65 | $4.71B est $4.32B | +1.7% |
| Nov 5, 2025 | $0.78 est $0.68 | $4.48B est $4.45B | +19.6% |
| Jul 30, 2025 | $0.66 est $0.63 | $4.18B est $4.36B | −6.6% |
| May 7, 2025 | $0.52 est $0.47 | $3.89B est $4.38B | +12.1% |
| Jan 29, 2025 | $0.71 est $0.70 | $4.23B est $4.10B | −17.1% |
| Nov 6, 2024 | −$0.39 est $0.66 | $4.33B est $4.12B | −6.8% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Teva Pharmaceutical Industries stock forecast and analyst price targets
Analysts’ average 12-month price target for Teva Pharmaceutical Industries is $42.00, +7.7% from the last close, from 9 firms rating the stock in the last 90 days.
$42.00consensus 12-month target, +7.7% from the last close
Now $38.98Avg $42.00
Low $40High $50
Each firm’s latest rating in the last 90 days: 9 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 9 | Leerink Partners | $45 | +15.4% |
| Sep 4 | UBS | $48 | +23.1% |
| Sep 3 | Scotiabank | $40 | +2.6% |
| Sep 3 | Jefferies | $40 | +2.6% |
| Sep 2 | Bank of America Securities | $43 | +10.3% |
+2.6%average 20-day move after past Neutral readings
−0.6%average move over the next 20 trading days in the last 5 years
±3.1%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Teva Pharmaceutical Industries seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, Teva Pharmaceutical Industries averaged −0.6% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.6% | 1 of 5 |
| Next 10 trading days | +1.1% | 2 of 5 |
| Next 15 trading days | +1.5% | 2 of 5 |
| Next 20 trading days | −0.6% | 3 of 5 |
| Next 30 trading days | +1.6% | 4 of 5 |
For scale, TEVA’s typical 20-trading-day move in either direction is about 7.9%.
Teva Pharmaceutical Industries market cap and key statistics
Teva Pharmaceutical Industries’s market cap is $45.40B, with a P/E ratio of 64.3 and revenue of $17.32B over the last twelve months.
Valuation
- Market cap
- $45.40B
- P/E ratio
- 64.3
- Forward P/E
- 12.6
- EPS, TTM
- $0.61
- Gekko Fair Value
- $31.56
Trading
- Volume
- 5.47M
- Avg volume, 20 days
- 4.65M
- 52-week high
- $39.70
- 52-week low
- $18.21
- Shares outstanding
- 1.17B
Financials
- Revenue, TTM
- $17.32B
- Profit margin
- 4.1%
- Return on equity
- 9.7%
- Quarterly earnings growth, YoY
- +72.2%
Risk and income
- Beta
- 0.87
- Typical daily move
- ±3.1%
- Typical 20-day move
- ±7.9%
Teva Pharmaceutical Industries stock news this week
Coverage of Teva Pharmaceutical Industries this week reads positive: 5 positive, 3 neutral and 0 negative headlines.
- New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older PatientsGlobeNewsWire, Sep 18
- Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare CostsGlobeNewsWire, Sep 18
- Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in AdultsGlobeNewsWire, Sep 18
- TEVA Price Today: Teva Pharmaceutical Industries Limited Stock Price, Quote & Chart | MEXCMEXC, Sep 17
- Most Active Options Report: FPS, TEVA, AFLSchaeffer's Investment Research, Sep 16
- Takeda Pharmaceutical (NYSE:TAK) versus Teva Pharmaceutical Industries (NYSE:TEVA) Financial ContrastDefense World, Sep 16
Teva Pharmaceutical Industries stock FAQ
What is Teva Pharmaceutical Industries’s market cap?
Teva Pharmaceutical Industries’s market cap is $45.40B at the Sep 18, 2026 close of $38.98, with 1.17B shares outstanding. The shares trade on a P/E ratio of 64.3.
What is the Teva Pharmaceutical Industries stock forecast?
The consensus analyst 12-month price target for Teva Pharmaceutical Industries is $42.00, +7.7% from the last close. Of the 9 firms that rated the stock in the last 90 days, 9 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Teva Pharmaceutical Industries stock overvalued or undervalued?
On Gekko’s estimate Teva Pharmaceutical Industries is overvalued: the Sep 18, 2026 close of $38.98 is 23.5% above Gekko Fair Value of $31.56. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Teva Pharmaceutical Industries report earnings next?
Teva Pharmaceutical Industries is expected to report on Nov 4, 2026, before the market opens (45 days away). Analysts expect earnings of $0.71 per share on revenue of $4.26B. Teva Pharmaceutical Industries beat the earnings estimate in 7 of its last 8 reports, moving 10.8% on average across the report.
What is Teva Pharmaceutical Industries’s 52-week high and low?
Teva Pharmaceutical Industries’s 52-week high is $39.70 and its 52-week low is $18.21; it closed at $38.98 on Sep 18, 2026, +112.1% over the past year.
Is Teva Pharmaceutical Industries stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and seasonality) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Teva Pharmaceutical Industries the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.